4,375 results on '"denosumab"'
Search Results
2. Sandoz Canada announces launch of Jubbonti, Wyost
3. Organon, Shanghai Henlius Biotech: EMA validates MAAs for HLX14
4. Sandoz receives EC approval for Wyost, Jubbonti in Europe
5. Dr. Reddy's, Alvotech enter into collaboration for commercialization of AVT03
6. Sandoz, Amgen to resolve all patent disputes relating to denosumab biosimilars
7. Amgen settlement with Sandoz a positive, says Jefferies
8. BeiGene price target lowered by $15 at BofA, here's why
9. Cognition Therapeutics Inc To Host KOL Event - Final
10. US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
11. Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
12. Teva's Prolia biosimilar candidate accepted for review by FDA and EMA
13. Introducing Jubbonti(R) and Wyost(R), the first denosumab biosimilars on the Canadian market
14. Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia(R) and Xgeva(R)
15. New Efficacy Data for Non-Clear Cell Renal Cell Carcinoma From KEYNOTE-B61 Added to LENVIMA (lenvatinib) US Label Supporting KEYTRUDA + LENVIMA Indication for the First-Line Treatment of Adult Patients With Advanced RCC
16. New Post-Hoc Analysis from Phase 3 REFLECT Trial Presented at ESMO GI 2024 Explores Efficacy Outcomes with LENVIMA (lenvatinib) Based on Depth of Tumor Response in Unresectable Hepatocellular Carcinoma
17. Amneal adds 2 denosumab biosimilars to U.S. pipeline oncology portfolio
18. Reports from Leeds Teaching Hospitals NHS Trust Highlight Recent Findings in COVID-19 (An Audit To Assess Whether Patients Who Had a Delayed or Missed Denosumab Dose During the Covid-19 Pandemic Came To Any Harm or Suffered a Subsequent Fracture)
19. Alvotech and STADA expand partnership for denosumab biosimilar
20. Patent Application Titled 'Biomarker For Diagnosis, Treatment, And Prognosis For Hepatocellular Carcinoma Bone Metastasis And Application Thereof' Published Online (USPTO 20240168027)
21. Sandoz receives European Commission approval for Wyost(R) and Jubbonti(R), the first and only biosimilars of denosumab in Europe
22. Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia[R] & Xgeva[R] in the U.S., Europe and UK
23. Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia(R) & Xgeva(R) in the U.S., Europe and UK
24. Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
25. Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
26. Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
27. MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China
28. FDA Roundup: March 5, 2024
29. Sandoz receives FDA approval for first and only denosumab biosimilars
30. MHRA grants first approval via the new International Recognition Procedure in 30 days
31. EMA accepts Sandoz marketing authorization applications for biosimilar denosumab
32. Sandoz receives Health Canada approval for Jubbonti(R), first and only denosumab biosimilar for treatment of osteoporosis
33. Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia(R) and Xgeva(R)
34. Patent Application Titled 'Sternal Reconstruction Interface' Published Online (USPTO 20240148419)
35. Luye Pharma: Boan Biotech today announced that Boluojia, a denosumab injection (120mg) developed by the company, has been approved for marketing by China's National Medical Products Administration (NMPA) for the treatment of giant cell tumor of
36. European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia and Xgeva (denosumab) Biosimilar Candidate HLX14
37. Study Findings from Leeds Teaching Hospitals NHS Trust Advance Knowledge in COVID-19 (P001 An audit to assess whether patients who had a delayed or missed denosumab dose during the covid-19 pandemic came to any harm or suffered a subsequent ...)
38. Patent Issued for Modulation of an individual's gut microbiome to address osteoporosis and bone disease (USPTO 11951140)
39. FDA Roundup: March 5, 2024
40. Biosimilars Pipeline Report: Comprehensive Analysis of Prolia & Xgeva Denosumab Candidates Emerges - ResearchAndMarkets.com
41. Biosimilars Pipeline Report: Comprehensive Analysis of Prolia & Xgeva Denosumab Candidates Emerges
42. Not just your grandmother's disease: A new look at bone health
43. Novartis' Sandoz reports on denosumab integrated Phase I/III clinical trial
44. 'Dean of Asian Myeloma' Dr. Kazuyuki Shimizu to Receive First Asian Myeloma Network (AMN) Distinguished Service Award
45. Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
46. Organon in pact to commercialize pertuzumab and denosumab biosimilar candidates
47. Case review: Metastatic castrate-resistant prostate cancer in a 65-year-old man
48. Entera Bio Ltd To host key opinion leader webinar - Final
49. Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
50. CSPC's Class 1 New Drug Narusobizumab Approved for Marketing
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.